Dan Vogl, MD, offers an update from the 2016 meeting of the American Society of Hematology on recent advances in relapsed myeloma, a discussion involving approved and experimental treatments currently available (daratumumab, venetoclax, nelfinavir, ibrutinib, vemurafenib) those in clinical trials only (selinexor), and expected development in the near future. Dr. Vogl’s discussion includes an overview of the many clinical trials in relapsed/refractory myeloma ongoing at Penn Medicine.
Related Links:
Published
March 14, 2017
Created by
BROADCASTMED